このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics (PAC)

2026年5月28日 更新者：Raymond P. Najjar, PhD、National University of Singapore

Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics (PAC)

The goal of this study is to understand how caffeine and alcohol affect the ocular and physiological systems, especially how the pupil (the aperture in the colored part of the eye) responds to light. It will also test whether these changes can be used to detect recent caffeine or alcohol intake using a portable eye device.

The main questions it aims to answer are:

  1. How does caffeine change pupil responses, eye movements, and other ocular and physiological measurements?
  2. How does alcohol change these same ocular and physiological responses?
  3. Are the effects of caffeine and alcohol different from each other?
  4. Can these changes be used to accurately identify whether someone has consumed caffeine or alcohol?

Researchers will compare caffeine, alcohol, and a placebo (a look-alike drink with no active substance) to see how each affects the ocular and physiological outcomes.

Participants will:

  1. Attend three separate sessions where they will consume caffeine, alcohol, or a placebo (in random order)
  2. Undergo pupillary response evaluation using a handheld device that measures responses to different colored light stimuli
  3. Have their eye movements analyzed
  4. Have retinal and choroidal thickness, blood perfusion, and ocular oxygen levels measured
  5. Have basic body measurements recorded (such as pulse rate and blood pressure)
  6. Complete tests at multiple time points over 2 hours after consumption

The results of this study may help develop a quick and non-invasive way to detect recent caffeine or alcohol use for clinical and safety purposes.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Caffeine and alcohol are widely consumed psychoactive substances that affect the central and autonomic nervous systems. These effects can influence ocular function, including pupil responses to light, eye movements, and retinal physiology. However, objective and non-invasive methods to detect and differentiate these effects remain limited.

The pupillary light reflex is a sensitive indicator of autonomic nervous system activity. Chromatic pupillometry, which uses different colored light stimuli, allows assessment of specific retinal pathways and provides detailed information about pupil function. This study aims to determine whether changes in pupillary responses and other ocular measurements can be used to detect recent caffeine or alcohol consumption.

Study Design and Procedures A total of 100 healthy adults aged 30-50 years will participate in this study.

Each participant will attend three study visits, corresponding to the following conditions:

  1. Caffeine condition (~3 mg/kg)
  2. Alcohol condition (target blood alcohol concentration ~0.05%)
  3. Placebo condition The order of conditions will be randomized. This is a double-masked, within-subject crossover study, where each participant undergoes all three conditions.

Study Visit Procedures

At each visit, participants will receive one tablet and one beverage according to the assigned condition:

  1. Placebo condition: placebo tablet with a non-alcoholic beverage
  2. Alcohol condition: placebo tablet with an alcohol-containing beverage
  3. Caffeine condition: caffeine tablet with a non-alcoholic beverage Procedures will be standardized to maintain masking, and study personnel performing assessments will remain unaware of the assigned condition.

Assessments All measurements will be performed at baseline (before consumption) and at 30, 60, 90, and 120 minutes after consumption, unless otherwise specified.

  1. Pupillary Assessment: Pupillary responses will be measured using a handheld chromatic pupillometry device in a controlled dark environment. Different colored light stimuli will be used to assess pupil function.
  2. Eye Movement Analysis: Eye movements will be recorded to evaluate oculomotor function, including tracking, fixation, and gaze behavior at baseline, 60 minutes, and 120 minutes.
  3. Retinal and Choroidal Imaging: Retinal and choroidal thickness and blood perfusion will be measured using optical coherence tomography (OCT) and OCT angiography at baseline, 60 minutes, and 120 minutes.
  4. Breath Alcohol Measurement: Breath alcohol concentration will be measured using a breathalyzer at all time points to monitor alcohol levels.
  5. Physiological Measurements: Basic physiological parameters will be recorded, including: Pulse rate, Blood pressure, Blood Oxygen saturation

Data Analysis Data from pupillary responses, eye movements, retinal imaging, and physiological measurements will be combined to identify patterns associated with caffeine and alcohol intake.

Expected Outcomes This study aims to identify measurable changes in pupil responses and other ocular parameters following caffeine and alcohol consumption. It will also evaluate whether a portable, non-invasive system can be used to detect alcohol and caffeine consumption.

The findings may support the development of rapid and objective screening tools for clinical, occupational, and public safety applications.

研究の種類

介入

入学 (推定)

100

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前：Vicknaswari T, Bsc Optometry
  • 電話番号：+6565165459
  • メール：tv96@nus.edu.sg

研究連絡先のバックアップ

研究場所

  • シンガポール
      • Singapore、シンガポール、119276
        • 募集
        • National University of Singapore, E7 Building, Level 7, 15 Kent Ridge Cres
        • 主任研究者：
          • Raymond P. Najjar, PhD
        • コンタクト：
          • Vicknaswari T, BSc
          • 電話番号：+6565165459
          • メール：tv96@nus.edu.sg
        • コンタクト：
        • 副調査官：
          • Najiya S.K. Meethal, PhD
        • 副調査官：
          • Catherina Josephine Goenadi, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Participants must meet the inclusion criteria, as shown below, to participate in this study

Inclusion Criteria

  1. Age: 30 to 50 years of age
  2. Visual Acuity: Best Corrected Visual Acuity (BCVA) of 0.20 LogMAR or better in both eyes
  3. Ability to provide informed consent: Participants must be able to understand and sign the informed consent form
  4. Ability to consume both caffeine and alcohol: Participants must be willing and able to consume caffeine and alcohol as part of the study

Participants meeting any of the exclusion criteria, as shown in the table below, will be excluded from participation.

Exclusion Criteria

  1. Diagnosed ocular conditions: Participants with ocular or ocular movement diseases such as glaucoma, age-related macular degeneration, diabetic retinopathy, amblyopia, severe ptosis, or conditions relating to pupils: anisocoria, irregular pupil, Adie tonic, Horner's syndrome, Argyll Robertson pupil, etc. These exclude cataracts, refractive errors, and any ocular condition not affecting vision or ocular movement or obstructing the pupil.
  2. Diagnosed and unresolved neurological conditions:Stroke, unresolved traumatic brain injury, space-occupying lesions in the brain, neuropathies, demyelinating conditions, nerve palsies, etc.
  3. Diagnosed systemic conditions that may restrict the participant from drinking caffeine or alcohol: Hypertension, cardiovascular disease, liver disease, kidney disease, etc.
  4. Medications: Participants taking any medications that may interact with caffeine or alcohol, affect alertness, or cause drowsiness
  5. Previous complex intraocular eye surgery: Participants who have undergone any eye surgery other than uncomplicated refractive surgery.
  6. Pregnancy or breastfeeding: Pregnant or breastfeeding women will be excluded from the study, as caffeine and alcohol can affect the fetus or baby
  7. History of substance abuse: Participants with a history of substance abuse
  8. Allergies or sensitivities: Participants with allergies or sensitivities to caffeine or alcohol
  9. Shift work or having travelled across 2 time zones over the past 2 weeks: This is essential to avoid any impact of sleep deprivation on our outcome measures
  10. Non-consumers or light-consumers of caffeine and alcohol Participants who are light consumers of caffeine or alcohol will be excluded due to higher sensitivity to side effects.

Caffeine: If less than 100 mg of caffeine per week from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ* Alcohol: If AUDIT-C** score less than 1

11- Extremely frequent consumers Participants who are extremely frequent consumers of caffeine or alcohol will be excluded due to potential withdrawal symptoms during the required 18-hour abstinence and possible reduced sensitivity to administered doses.

Caffeine: If more than 400mg of caffeine (e.g., 5 espressos) per day from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ* Alcohol: If AUDIT-C** scores more than 4 for men and more than 3 for women

Note: Participants will complete a history update questionnaire at each laboratory visit to report any changes relevant to the exclusion criteria. If a participant no longer meets the eligibility criteria at any visit after the baseline assessment, the visit will either be rescheduled, if appropriate, or the participant will be withdrawn from the study. Reimbursement will be provided on a prorated basis.

*CCQ: Caffeine Consumption Questionnaire

**AUDIT-C: Alcohol Use Disorders Identification Test-C

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：診断
  • 割り当て：ランダム化
  • 介入モデル：クロスオーバー割り当て
  • マスキング：トリプル

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター：Placebo
Participants receive placebo tablets and non-active beverage under double-masked crossover conditions.
他の：Placebo Comparator: Placebo
Participants receive a matched placebo tablet together with a non-alcoholic beverage identical in appearance and volume to the active conditions. A cornstarch-based formulation may be used for the placebo tablet. Beverage presentation is standardized to maintain blinding across study conditions. No active caffeine or alcohol is administered.
実験的：Caffeine
Participants receive caffeine administration under double-masked crossover conditions.
他の：Caffeine administration
Participants receive a single oral dose of caffeine (~3 mg/kg body weight) administered in tablet form. The caffeine is given with a non-alcoholic beverage matched to study conditions. All procedures are performed under randomized, double-masked crossover design conditions.
実験的：Alcohol
Participants receive alcohol administration under double-masked crossover conditions.
他の：Alcohol (Ethanol)
Participants consume a standardized alcoholic beverage designed to achieve a target blood alcohol concentration of approximately 0.05%. A placebo tablet is administered alongside the beverage to maintain masking. All procedures are performed under randomized, double-masked crossover design conditions.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Baseline Pupil Size
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Baseline pupil size will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Baseline pupil size refers to the resting pupil diameter measured prior to light stimulation. It is measured in pixels.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Phasic Pupil Constriction to Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Phasic pupil constriction to blue light will be quantified using handheld chromatic pupillometry. Phasic pupil constriction to blue light refers to the rapid, transient decrease in pupil diameter that occurs immediately after the onset of a blue light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum Pupil Constriction to Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum pupil constriction to blue light will be quantified using handheld chromatic pupillometry. Maximum pupil constriction to blue light refers to the greatest reduction in pupil diameter observed following the onset of a blue light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil Constriction Latency to Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil constriction latency to blue light will be quantified using handheld chromatic pupillometry. Constriction latency is defined as the time from blue light onset to the first detectable decrease in pupil diameter relative to baseline. It is measured in seconds or milliseconds.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Phasic Pupil Constriction to Red Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Phasic pupil constriction to red light will be quantified using handheld chromatic pupillometry. Phasic pupil constriction to red light refers to the rapid, transient decrease in pupil diameter that occurs immediately after the onset of a red light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum Pupil Constriction to Red Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum pupil constriction to red light will be quantified using handheld chromatic pupillometry. Maximum pupil constriction to red light refers to the greatest reduction in pupil diameter observed following the onset of a red light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil Constriction Latency to Red Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil constriction latency to red light will be quantified using handheld chromatic pupillometry. Constriction latency is defined as the time from red light onset to the first detectable decrease in pupil diameter relative to baseline. It is measured in seconds or milliseconds.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Phasic Pupil Constriction to Continuous White Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Phasic pupil constriction to continuous white light will be quantified using handheld chromatic pupillometry. Phasic pupil constriction to white light refers to the rapid, transient decrease in pupil diameter that occurs immediately after the onset of a white light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum Pupil Constriction to Continuous White Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum pupil constriction to continuous white light will be quantified using handheld chromatic pupillometry. Maximum pupil constriction to white light refers to the greatest reduction in pupil diameter observed following the onset of a white light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil Constriction Latency to Continuous White Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil constriction latency to continuous white light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Constriction latency is defined as the time from white light onset to the first detectable decrease in pupil diameter relative to baseline. It is measured in seconds.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum Pupil Constriction to White Light Flash
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Maximum pupil constriction to white light flash will be quantified using using handheld chromatic pupillometry. Maximum pupil constriction to white light refers to the greatest reduction in pupil diameter observed following the onset of a white light stimulus. It is calculated as a percentage change from baseline.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-Stimulus Pupil Recovery Slope to Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-stimulus pupil recovery slope to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a blue light stimulus. It is calculated as percentage change per second.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil Slope to Blue Light 1.7s before Blue Light Offset
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil slope to blue light 1.7s before blue light offset will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Pupil slope to blue light within the last 1.7s refers to the rate of pupil re-dilation just before the offset of a blue light stimulus. It is calculated as percentage change per second.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil Slope to Blue Light 1.7s after Blue Light Offset
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pupil slope to blue light in the 1.7s after blue light offset will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Pupil slope to blue light in the 1.7s after blue light offset refers to the rate of pupil re-dilation just after the offset of a blue light stimulus. It is calculated as percentage change per second.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-Stimulus Pupil Recovery Slope to Red Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-stimulus pupil recovery slope to red light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a red light stimulus. It is calculated as percentage change per second.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-Stimulus Pupil Recovery Slope to White Light Flash
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-stimulus pupil recovery slope to white light flash will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a white light stimulus. It is calculated as percentage change per second.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-Stimulus Pupil Recovery Slope to Continuous White Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-stimulus pupil recovery slope to continuous white light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a white light stimulus. It is calculated as percentage change per second.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR at 6 s - Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after blue light offset. It is calculated as a percentage of baseline pupil size.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR at 12 s - Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 12 s is measured as pupil size at 12 seconds after blue light offset. It is calculated as a percentage of baseline pupil size.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR Area Under the Curve (0-12 s) - Blue Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR area under the curve (AUC) from 0 to 12 seconds captures the total magnitude and duration of the sustained post-illumination response. It is calculated as the integrated area in %.s.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR at 6 s - Red Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to red light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after red light offset. It is calculated as a percentage of baseline pupil size.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR Area Under the Curve - Red Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to red light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR area under the curve (AUC) from 0 to end of recording captures the total magnitude and duration of the sustained post-illumination response. It is calculated as the integrated area in %.s.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR at 6 s - Flash White Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to white light flash will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after white light offset. It is calculated as a percentage of baseline pupil size.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
PIPR at 6 s - Continuous White Light
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Post-illumination pupillary responses (PIPR) to continuous white light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after white light offset. It is calculated as a percentage of baseline pupil size.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

二次結果の測定

結果測定
メジャーの説明
時間枠
Retinal Thickness
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Retinal thickness will be assessed using Triton swept-source optical coherence tomography (SS-OCT). Retinal thickness is defined as the axial distance between the internal limiting membrane and the retinal pigment epithelium, measured in micrometres (µm), and is automatically quantified across the nine ETDRS subfields of the 12 × 9 mm macular volume scan.
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Choroidal Thickness
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Choroidal thickness will be assessed using swept-source optical coherence tomography (SS-OCT). Choroidal thickness is defined as the perpendicular distance between the outer boundary of Bruch's membrane and the chorioscleral interface, measured in micrometres (µm), and is automatically segmented across the nine ETDRS subfields.
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Superficial Capillary Plexus Vessel Density
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Vessel density of the superficial capillary plexus (SCP) will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the SCP is automatically segmented by the built-in IMAGEnet software. Vessel density is defined as the proportion of the measurement area occupied by detected blood flow signals, reported as a percentage (%) across the whole image and individual ETDRS subfields.
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Deep Capillary Plexus Vessel Density
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Vessel density of the deep capillary plexus (DCP) will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the DCP is automatically segmented by the built-in IMAGEnet software. Vessel density is defined as the proportion of the measurement area occupied by detected blood flow signals, reported as a percentage (%) across the whole image and individual ETDRS subfields.
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Choriocapillaris Vessel Density
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Choriocapillaris vessel density will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the choriocapillaris slab is automatically segmented from 0 to 10.4 µm below the outer boundary of Bruch's membrane. Vessel density is defined as the proportion of the measurement area exhibiting detectable flow signal relative to the total sampled area, reported as a percentage (%).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Foveal Avascular Zone Area
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Foveal avascular zone (FAZ) area will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the FAZ is automatically delineated at the level of the superficial capillary plexus by the built-in IMAGEnet software. FAZ area is defined as the area of the capillary-free region centred on the fovea, measured in square millimetres (mm²).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Choroidal Vascularity Index
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
The choroidal vascularity index (CVI) will be derived from the subfoveal horizontal B-scan of the 12 × 9 mm SS-OCT macular scan. The segmented choroidal region, bounded by Bruch's membrane and the chorioscleral interface, is binarised into luminal (vascular) and stromal areas. CVI is calculated as the ratio of luminal choroidal area to total choroidal area, expressed as a percentage (%).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Prosaccade Latency
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Prosaccade latency will be assessed using eye tracking. Prosaccade latency refers to the time interval between the onset of a visual target and the initiation of the corresponding prosaccade eye movement. It is measured in milliseconds (ms).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Prosaccade Peak Velocity
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Prosaccade peak velocity will be assessed using eye tracking. Prosaccade peak velocity refers to the maximum angular velocity achieved during a prosaccade movement. It is measured in degrees per second (°/s).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Prosaccade Amplitude
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Prosaccade amplitude will be assessed using eye tracking. Prosaccade amplitude refers to the total angular displacement of the eye during a prosaccade movement. It is measured in degrees (°).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Smooth Pursuit Gain
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Smooth pursuit gain will be assessed using eye tracking. Smooth pursuit gain refers to the ratio of eye velocity to target velocity during smooth pursuit tracking, where a value of 1.0 indicates perfect tracking. It is expressed as a unitless ratio.
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Catch-Up Saccade Frequency During Smooth Pursuit
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Catch-up saccade frequency will be assessed using eye tracking. Catch-up saccade frequency refers to the number of corrective saccades per second that occur during smooth pursuit tracking, reflecting the degree of pursuit impairment. It is measured as events per second (events/s).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Smooth Pursuit Tracking Accuracy
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Smooth pursuit tracking accuracy will be assessed using eye tracking. Smooth pursuit tracking accuracy refers to the proportion of time the eye position is within an acceptable error window of the pursuit target trajectory. It is calculated as a percentage (%).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Micro-Saccade Rate During Fixation
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Micro-saccade rate will be assessed using eye tracking during a sustained fixation task (30-60 s). Micro-saccade rate refers to the number of micro-saccade events per second during sustained fixation, reflecting fixation stability and cortical arousal. It is measured as events per second (events/s).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Fixation Dispersion
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Fixation dispersion will be assessed using eye tracking during a sustained fixation task (30-60 s). Fixation dispersion refers to the angular spread of gaze position around the fixation target during sustained fixation, quantifying the spatial extent of fixation instability. It is measured in degrees (°).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Fixation Duration During Free Viewing
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Fixation duration during free viewing will be assessed using eye tracking. Fixation duration refers to the mean duration of individual fixations during free viewing of a standardised stimulus, reflecting attentional dwell time. It is measured in milliseconds (ms).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Scanpath Variability During Free Viewing
時間枠：Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Scanpath variability during free viewing will be assessed using eye tracking. Scanpath variability refers to the angular variability of the gaze trajectory during free viewing, characterising the spread and consistency of spontaneous viewing patterns. It is measured in degrees (°).
Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

その他の成果指標

結果測定
メジャーの説明
時間枠
Breath Alcohol Concentration
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Breath alcohol concentration (BrAC) will be measured using a handheld breathalyzer. BrAC refers to the ethanol concentration in exhaled breath, converted to estimated blood alcohol concentration (BAC) using a standard 1:2100 partition ratio. A target BAC of 0.04-0.06% corresponds to an approximate BrAC of 0.04-0.06 mg/210L. It is measured in mg/210L.
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Peripheral Oxygen Saturation (SpO₂)
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Peripheral oxygen saturation (SpO₂) will be measured using a pulse oximeter. SpO₂ refers to the estimated percentage of oxyhaemoglobin relative to total haemoglobin in peripheral blood, providing a non-invasive measure of systemic oxygenation. It is measured as a percentage (%).
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pulse Rate
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Pulse rate will be measured using automated sphygmomanometry. Pulse rate refers to the number of arterial pulsations per minute, reflecting heart rate and cardiovascular autonomic response to intervention. It is measured in beats per minute (bpm).
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Systolic Blood Pressure
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Systolic blood pressure will be measured using automated sphygmomanometry. Systolic blood pressure refers to the peak arterial pressure during cardiac contraction, reflecting cardiovascular autonomic response to intervention. It is measured in millimetres of mercury (mmHg).
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Diastolic Blood Pressure
時間枠：Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Diastolic blood pressure will be measured using automated sphygmomanometry. Diastolic blood pressure refers to the minimum arterial pressure during cardiac relaxation, reflecting cardiovascular autonomic response to intervention. It is measured in millimetres of mercury (mmHg).
Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)
Weight
時間枠：Baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)
Weight of participant in kilograms
Baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)
Height
時間枠：Baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)
Height of the participant in meters
Baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)
Body Mass Index (BMI)
時間枠：Calculated at baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)
Calculated as participant's weight in kilograms divided by the square of participant's height in meters (kg/m^2).
Calculated at baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

National University of Singapore

協力者

Home Team Science & Technology Agency (HTX)

捜査官

  • 主任研究者：Raymond P. Najjar, PhD、Department of Ophthalmology, National University of Singapore (NUS)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2027年5月5日

研究の完了 (推定)

2027年11月5日

試験登録日

最初に提出

2026年5月18日

QC基準を満たした最初の提出物

2026年5月28日

最初の投稿 (実際)

2026年6月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月4日

QC基準を満たした最後の更新が送信されました

2026年5月28日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • NUS-IRB-2025-1150

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

Individual participant data (IPD) may not be shared due to participant confidentiality, privacy protection, and compliance with institutional or sponsor and regulatory data governance policies.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する